Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

BACKGROUND: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib. METHODS: Patients with KRAS mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Macarulla, T, Cervantes, A, Tabernero, J, Roselló, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B, Jego, V, von Richter, O, Ciardiello, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580393/
https://www.ncbi.nlm.nih.gov/pubmed/25989270
http://dx.doi.org/10.1038/bjc.2015.144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580393/
https://www.ncbi.nlm.nih.gov/pubmed/25989270
http://dx.doi.org/10.1038/bjc.2015.144

Ejemplares similares